SPOT-ON SKIN LIPID COMPLEXAS AN ADJUNCT THERAPY INDOGS WITH ATOPIC DERMATITISAN OPEN PILOT STUDY Elin Põldemaa 2011
OUTLINE Introduction Methods Results Conclusions Refrences
INTRODUCTION Atopic dermatitis (AD) is a common allergic skin  disease in both people and dogs The treatment of dogs wit...
METHODS The investigators recruited 8 dogs from their hospital  with a diagnosis of chronic AD and persistent pruritus  d...
RESULTS After 6 weeks of SLC treatment, a substantial  improvment in the dogs condition occured It was caused by the red...
Clinicalcharacteristicsof Dog 5 atstart of thetreatment (D0)
6 weeksafter D0
12 weeksaftertreatment
The dog wastreatedcontinuously afterthe completion ofthe trial. Clinicalsymptomsimproved 18weeks after D0.
CONCLUSIONS       The results of this study suggest that topical SLCapplication is beneficial when used in the management ...
REFRENCES“Spot-On Skin Lipid Complex as an Adjunct Therapyin Dogs with Atopic Dermatitis: An Open Pilot Study“Masato Fujim...
THANK YOU FOR YOUR ATTENTION!
Upcoming SlideShare
Loading in …5
×

Spot on skin lipid complex as an adjunct therapy in dogs with AD

487 views
352 views

Published on

Published in: Lifestyle, Health & Medicine
1 Comment
0 Likes
Statistics
Notes
  • Be the first to like this

No Downloads
Views
Total views
487
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
6
Comments
1
Likes
0
Embeds 0
No embeds

No notes for slide

Spot on skin lipid complex as an adjunct therapy in dogs with AD

  1. 1. SPOT-ON SKIN LIPID COMPLEXAS AN ADJUNCT THERAPY INDOGS WITH ATOPIC DERMATITISAN OPEN PILOT STUDY Elin Põldemaa 2011
  2. 2. OUTLINE Introduction Methods Results Conclusions Refrences
  3. 3. INTRODUCTION Atopic dermatitis (AD) is a common allergic skin disease in both people and dogs The treatment of dogs with AD is complex and lifelong The aim of this study was to evaluate the clinical benefits of topical Spot-On Skin Lipid Complex (SLC) in the treatment of dogs with chronic AD The study took place in Fujimura Animal Allergy Hospital, Japan, from September 2009 to December 2009
  4. 4. METHODS The investigators recruited 8 dogs from their hospital with a diagnosis of chronic AD and persistent pruritus despite therapy. The dogs were treated with SLC topically as adjunct therapy for 12 weeks. A topical SLC product containing ceramides, cholesterol and free fatty acids was applied at a dose of 2 mL twice weekly, by applying several drops on the head, inter scapular area, and directly on lesion sites
  5. 5. RESULTS After 6 weeks of SLC treatment, a substantial improvment in the dogs condition occured It was caused by the reduction in the erythema (36.2%, p<0,005), excoriation (39,9%, p<0,05) and alopecia subscores (19.9%, p<0,05). There were no markable advances in the treatment of lichenification as the decrease rate was statistically unimportant. For the evaluation of the efficency of SLC therapy, the third version of the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) modification was used
  6. 6. Clinicalcharacteristicsof Dog 5 atstart of thetreatment (D0)
  7. 7. 6 weeksafter D0
  8. 8. 12 weeksaftertreatment
  9. 9. The dog wastreatedcontinuously afterthe completion ofthe trial. Clinicalsymptomsimproved 18weeks after D0.
  10. 10. CONCLUSIONS The results of this study suggest that topical SLCapplication is beneficial when used in the management ofcanine AD. Topical lipid applications are not effective as monotherapy but as an adjunct therapy they may bring new hope in the treatment of canine AD Although the findings are encouraging, double-blinded placebo-controlled or cross-over studies are needed to confirm the results. The drug-sparing effects of SLC applications also deserve further investigation
  11. 11. REFRENCES“Spot-On Skin Lipid Complex as an Adjunct Therapyin Dogs with Atopic Dermatitis: An Open Pilot Study“Masato Fujimura, Yoshinobu Nakatsuji, SubaruFujiwara, Christophe Rème and Hugues GattoVeterinary Medicine International, Volume 2011http://www.hindawi.com/journals/vmi/2011/281846/
  12. 12. THANK YOU FOR YOUR ATTENTION!

×